Oncology Based In-Vivo CRO

A Global Strategic Business Report

MCP22417

RESEARCH DASHBOARD

OCT 2025

RELEASE DATE

844

EXECUTIVE POOL

5850

PRICE

169

EXPERT INPUTS

42

COMPANIES

57

DATA TABLES

129

PAGES

4

EDITION

WHAT'S BEHIND OUR DATA?

140857226

DOMAIN TRANSCRIPTS

6080276

BRANDS TRACKED

1729341

FEATURED COMPANIES

22574

TOPICS COVERED

82719

MARKET SEGMENTS

91

KEY INDUSTRIES

1574

CURATION TEAM

4761909

DECISION MAKERS

EXECUTIVE ENGAGEMENTS BY TIER (3414)

183

CXO

337

VICE PRESIDENT

763

DIRECTOR

1322

MANAGER

809

MARKETING

REQUEST FULL-STACK INDEX Includes 350+ pages validated sources

QUESTIONNAIRE EXECUTIVES DATA ROOM

OUR EXPERT PANELS

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

INFLUENCER INVITEE

WHY PARTICIPATE?

Expertise to the Power of YOU!

Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription

The Economist
MIT Technology Review
Harvard Business Review

Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.

MARKETGLASS

BASIC

Annual Prepaid Subscription
Single-User
10,000 Data Room Credits/Month
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use MarketGlass^TM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.

PREMIUM

Annual Prepaid Subscription
One Research Project With One Complimentary Update/Year
10-User License
10-User Peer-to-Peer Collaborative Features
200 Domain Expert Insights (With Name, Company, and Date)
50,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

ENTERPRISE

Annual Prepaid Subscription
Four Research Projects With One Complimentary Update/Year
25-User License
25-User Peer-to-Peer Collaborative Engagements
500 Domain Expert Insights (With Name, Company, and Date)
150,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

HIGHLIGHTS & REPORT INDEX

Global Oncology Based In-Vivo CRO Market to Reach US$2.5 Billion by 2030

The global market for Oncology Based In-Vivo CRO estimated at US$1.6 Billion in the year 2024, is expected to reach US$2.5 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Solid Tumors, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Blood Cancer segment is estimated at 5.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$455.3 Million While China is Forecast to Grow at 6.6% CAGR

The Oncology Based In-Vivo CRO market in the U.S. is estimated at US$455.3 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$383.5 Million by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.6% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.7% CAGR.

Global Oncology Based In-Vivo CRO Market - Key Trends and Drivers Summarized

How Is Oncology Based In-Vivo CRO Supporting Cancer Research?

Oncology-based In-Vivo Contract Research Organizations (CROs) provide specialized services for preclinical testing of cancer therapies in live animal models. These CROs offer comprehensive in-vivo studies, including pharmacology, toxicology, and efficacy assessments, enabling pharmaceutical and biotech companies to evaluate the potential of new cancer drugs before clinical trials. By utilizing animal models that mimic human cancer conditions, CROs help researchers understand drug behavior, dosage optimization, and side effects. The growing complexity of cancer treatments, which now include immunotherapies, targeted therapies, and gene therapies, has increased the demand for specialized in-vivo studies to ensure safety and efficacy.

What Are the Key Segments in the Oncology Based In-Vivo CRO Market?

Key services include pharmacokinetics (PK), pharmacodynamics (PD), toxicology, and efficacy testing, with pharmacokinetics and pharmacodynamics being the most in-demand services due to their importance in early-stage drug development. The application segment covers different cancer types, such as lung cancer, breast cancer, colorectal cancer, and blood cancers, with lung and breast cancer studies accounting for a significant share due to their high prevalence and active drug development pipelines. Major end-users include pharmaceutical companies, biotechnology firms, and academic research institutions, all of which rely on in-vivo CROs to advance their oncology drug discovery efforts.

How Are In-Vivo CROs Integrated Into Oncology Research?

Pharmaceutical companies collaborate with in-vivo CROs to conduct preclinical testing for new cancer treatments, reducing the time and cost associated with drug development. These CROs offer tailored in-vivo models, including patient-derived xenografts (PDX), syngeneic models, and transgenic models, to accurately represent human tumor biology. Biotechnology firms, often focusing on novel therapies like CAR-T cells and bispecific antibodies, use in-vivo CROs for efficacy and safety evaluations before moving to clinical trials. Academic and research institutions also work with CROs to study the mechanisms of action of potential cancer therapies and identify promising drug candidates. The integration of advanced technologies, such as imaging tools and biomarker analysis, has enhanced the accuracy and relevance of in-vivo studies in oncology research.

What Factors Are Driving the Growth in the Oncology Based In-Vivo CRO Market?

The growth in the Oncology Based In-Vivo CRO market is driven by several factors, including the increasing prevalence of cancer, which has fueled demand for new therapies and accelerated drug development. The shift toward targeted and personalized treatments, such as immunotherapies and gene therapies, has necessitated the use of specialized in-vivo models that accurately mimic human tumors. Advancements in preclinical research tools, such as imaging techniques and biomarker analysis, have improved study accuracy and efficiency, supporting broader adoption. The rise in collaborations between CROs and biopharma companies, along with increased government funding for cancer research, has further contributed to market growth. Additionally, the growing number of biotech startups focused on innovative oncology therapies has boosted demand for in-vivo CRO services.

SCOPE OF STUDY

The report analyzes the Oncology Based In-Vivo CRO market by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Solid Tumors, Blood Cancer, Other Indications).

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World..

SELECT PLAYERS

Champion Oncology, Inc.; Charles River Laboratory; Covance; Crown Bioscience; Eurofins Scientific; EVOTEC; ICON Plc; Living Tumor Laboratory; MI Bioresearch, Inc.; Taconic Biosciences; The Jackson Laboratory; Wuxi AppTec; Xentech

AI INTEGRATIONS

We’re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy

How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind

Global Economic Update

Oncology Based In-Vivo CRO – Global Key Competitors Percentage Market Share in 2024 (E)

Competitive Market Presence - Strong/Active/Niche/Trivial for 42 Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Rising Demand for Cancer Research Spurs Growth in Oncology-Based In-Vivo CRO Market

Technological Advancements in Preclinical Models and Imaging Strengthen Business Case for Adoption

Growing Focus on Personalized Medicine and Immuno-Oncology Expands Addressable Market

Expansion of In-Vivo CROs in Drug Discovery, Translational Research, and Toxicology Fuels Market Growth

Increasing Adoption of In-Vivo Models in Target Validation, Biomarker Identification, and Efficacy Studies Expands Market Opportunities

Technological Innovations in Animal Models, Xenografts, and Patient-Derived Tumor Models Propel Market Expansion

Growing Use of In-Vivo CROs in Cell Therapy, Gene Therapy, and Antibody-Drug Conjugates (ADCs) Expands Market Potential

Focus on Achieving Faster Time-to-Market for New Therapies Strengthens Market for Oncology-Based In-Vivo CRO

Technological Advancements in High-Throughput Screening, Genomics, and Imaging Propel Market Growth

Increasing Focus on Integrating In-Vivo CROs with Big Data Analytics and Real-Time Monitoring Drives Adoption

Rising Demand for In-Vivo CRO Services in Immuno-Oncology, Radiotherapy, and CAR-T Therapy Strengthens Global Market

Expansion of Oncology-Based In-Vivo CROs in Rare Cancers, Pediatric Oncology, and Early-Phase Trials Expands Market Opportunities

4. GLOBAL MARKET PERSPECTIVE

World Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Oncology Based In-Vivo CRO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Oncology Based In-Vivo CRO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Solid Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Blood Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

World Oncology Based In-Vivo CRO Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030

III. MARKET ANALYSIS

UNITED STATES

Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)

USA Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

USA Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2015, 2025 & 2030

CANADA

Canada Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2015, 2025 & 2030

JAPAN

Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)

Japan Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2015, 2025 & 2030

CHINA

Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)

China Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

China Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2015, 2025 & 2030

EUROPE

Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)

Europe Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

Europe Historic Review for Oncology Based In-Vivo CRO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Oncology Based In-Vivo CRO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2015, 2025 & 2030

FRANCE

Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)

France Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

France Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2015, 2025 & 2030

GERMANY

Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)

Germany Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2015, 2025 & 2030

ITALY

Italy Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2015, 2025 & 2030

UNITED KINGDOM

Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)

UK Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

UK Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2015, 2025 & 2030

REST OF EUROPE

Rest of Europe Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2015, 2025 & 2030

ASIA-PACIFIC

Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)

Asia-Pacific Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2015, 2025 & 2030

REST OF WORLD

Rest of World Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of World Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Rest of World 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2015, 2025 & 2030

COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)	% VALIDATED RESEARCH *
Biond Biologics	%
Champions Oncology, Inc.	%
Charles River Laboratories International, Inc.	%
Crown Bioscience, Inc.	%
ICON Plc	%
Labcorp Drug Development	%
Reaction Biology	%
Scimega	%
Sino Biopharmaceutical	%
Small Machines, Inc.	%

* Login to Participate & View Data Stacks

* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlass^TM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.

View All Companies...

PARTICIPATE NOW!

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.

Scroll